Fibrogen CEO Conterno bought 27,800 shares at $35.47. After last year’s unexpected passing of founder and long-time helmsman Thomas Neff, FibroGen needed a permanent successor—and with its big roxadustat launch looming, that new CEO would ideally know the ropes in … Read more.
The Insomniac Hedge Fund Guy
The Insomniac Hedge Fund Guy provides market macro-analytics and public-file aggregation models for data-tracking purposes. Content should not be treated as individualized investment advice or a professional financial-planning directive. Past performance does not guarantee future performance cycles.
© 2026 Insomniac Hedge Fund Guy. All rights reserved.
Still awake · --:--